Tuesday, November 5, 2024
HomeTagsTumor Immunotherapy

Tumor Immunotherapy

Degron Therapeutics Co-Founder Provides New Strategy for Molecular Glue in Tumor Immunotherapy

Degron Therapeutics ("Degron"), a biotechnology company developing a new class of small-molecule medicines that target previously undruggable targets, announced research suggesting lenalidomide, a molecular...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics